# PersonGen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/persongen

- Industry: Biotechnology
- Headquarters: Suzhou Industrial Park, China
- Website: www.persongen.com.cn
- Latest round: Series B (Jan 19, 2026)
- Investors on record: 6

## About

Based in Suzhou, China, and established in 2010, PersonGen BioTherapeutics (Suzhou) Co. Ltd., trading as PersonGen, is a biopharmaceuticals company that focuses on the R&D of CAR-T and other cellular immunotherapies. The company passed the ISO9001 certification. Besides, the company has won many awards, including National High-Tech Enterprise, Jiangsu Double Innovation Talent Program, and Jiangsu Province Six Talents Peak Team. The company established postdoctoral incubation workstations and Suzhou Cancer Immunotherapy Engineering Technology Research Center. The company's R&D team members are more than 80% researchers with doctoral or master's degrees. The company has applied for 30 international patents, 18 registered trademarks, and published 30 research articles in journal magazines. Also, the company has registered CAR-T and CAR-NK clinical trials on Clinicaltrials.gov, and launched clinical trials by collaborating with more than 10 medical centers in China. In January 2026, PersonGen closed Series B+ funding from new investor Xingtai Capital.

The company provides cellular therapies and antibodies pipeline. Some cellular products have entered clinical trial stage, covering most hematologic malignancies and some solid tumors. The company has R&D capabilities from antigen binding domains, CAR structure optimization, CAR-T functional testing, to in vivo efficacy verification. The company has developed technology platforms, including a CAR structure and function verification platform, an in vivo efficacy verification platform, induced pluripotent stem cell (iPSC)-derived allogeneic cell therapy platform, and NanoBa bispecific antibody development platform.

The company generates revenue by doing R&D and providing cellular therapeutic drugs to treat cancer and other related products.
 The Series B+ funding raised in January 2026 will be used to advance the clinical research and industrialization of its cell immunotherapy products, further enhancing the company's competitiveness in the field of tumor immunotherapy.

## Funding rounds

- Series B, Jan 19, 2026 — Xingtai Capital
- Series B, Jan 10, 2022 — China International Capital Corporation, Huatai Zijin Investment, Huatong Capital, Panyi (Suzhou) Private Equity Fund
- Series A, May 26, 2021 — Sangel Capital

## Investors

- Sangel Capital (https://capitalatlas.ai/funds/sangel-capital) — Series A
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series B
- Huatong Capital — Series B
- Panyi (Suzhou) Private Equity Fund — Series B
- Xingtai Capital (https://capitalatlas.ai/funds/xingtai-capital) — Series B